Register Login

Selecta Biosciences Inc (SELB)

  • Event
  • June 13, 2022, 12:00 UTC

(10% Negative) SELECTA BIOSCIENCES, INC. (SELB) Announces Delay in data Trials for DISSOLVE II Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 6:43 a.m.

    📋 SELECTA BIOSCIENCES, INC. (SELB) - Clinical Trial Update

    Filing Date: 2022-06-13

    Accepted: 2022-06-13 08:00:49

    Event Type: Clinical Trial Update

    Event Details:

    Selecta Biosciences Inc (SELB) Announces Clinical Trial Update Selecta Biosciences Inc (SELB) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: data, eligible
    • Diseases/Conditions: DISSOLVE II, autoimmune diseases
    • Clinical Stage: Phase 3, Phase 3 study
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Sobi-•DISSOLVE I & II
    • Updated Timeline: Q1 2023-, Q4 2022
      • anticipated by the end of Q2 2022

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Selecta Biosciences Inc
    • CIK: 0001453687
    • Ticker Symbol: SELB
    • Period End Date: 2022-06-13
    • Document Type: 8-K

Search

News categories